千亿·国际(中国)唯一官方网站
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2023.09.28
Notification of publication of Corporate Communication
2023.09.28
2023 Interim Report
2023.08.30
千亿国际:2023年半年度报告
2023.08.30
千亿国际:2023年半年度报告摘要
2023.08.30
千亿国际:独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和...
2023.08.30
千亿国际:关于控股股东承诺不减持公司股份的公告
2023.08.30
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
2023.08.21
CHANGE OF FINANCIAL CONTROLLER
2023.08.21
千亿国际:独立董事关于第六届董事会第二次会议相关事项的独立意见
2023.08.21
千亿国际:关于变更财务总监的公告
第一页
上一页
14
15
16
17
18
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.